194
Participants
Start Date
June 30, 2006
Primary Completion Date
November 30, 2007
Study Completion Date
November 30, 2007
Abatacept
Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Placebo
Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Local Institution, Nagoya
Local Institution, Nagoya
Local Institution, Goshogawara-Shi
Local Institution, Chiba
Local Institution, Sendai
Local Institution, Fukui-shi
Local Institution, Fukui-shi
Local Institution, Fukuoka
Local Institution, Fukuoka
Local Institution, Kitakyushu-Shi
Local Institution, Higashi-Hiroshima-Shi
Local Institution, Sapporo
Local Institution, Sapporo
Local Institution, Sapporo
Local Institution, Kanzaki-Gun
Local Institution, Kato-Gun
Local Institution, Hitachi-Shi
Local Institution, Tsukuba
Local Institution, Sagamihara-Shi
Local Institution, Sendai
Local Institution, Sendai
Local Institution, Nagano
Local Institution, Tsukubo-Gun
Local Institution, Kawachinagano-Shi
Local Institution, Ureshino-Shi
Local Institution, Iruma-Gun
Local Institution, Kawagoe-Shi
Local Institution, Kitamoto-Shi
Local Institution, Hamamatsu
Local Institution, Kawachigun
Local Institution, Tochigi
Local Institution, Arakawa-Ku
Local Institution, Bunkyo-Ku
Local Institution, Bunkyo-Ku
Local Institution, Setagaya-Ku
Local Institution, Shinjuku-Ku
Local Institution, Takaoka-Shi
Local Institution, Chiba
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY